- Home
- Metabolic Health & Weight Management
- Tesamorelin 5mg Vial
Tesamorelin 5mg Vial
Vial - lyophilised powderSubcutaneous (SQ)5 mg
Tesamorelin is known for research and a defined medical use involving excess abdominal fat in adults with HIV associated lipodystrophy. It works through growth hormone signalling. That specific clinical history sets it apart, but it is not a general weight loss or body shaping promise.
Shipping Information
Shipping Information
Free Shipping
Decor Outdoor offers free regular shipping on all orders shipped to residential or commercial addresses within the contiguous United States. Orders are delivered Monday through Friday (excluding holidays).Drop Shipping
We are an online-only luxury furniture and lighting boutique, and do not have a warehouse. Consequently, all orders are drop shipped directly from our manufacturers to your door. If your order includes items from more than one manufacturer, you will receive multiple deliveries. Because we are dependent on the on-hand inventory of our manufacturing partners, some items listed on our site may not actually be available right away. Please call us at 888.784.4644 or via our contact form with any stocking questions and we'll get in touch with the appropriate manufacturer for answers, before you place your order.Ground Shipping
Small parcel items ship regular ground via delivery services such as FedEx, UPS or DHL. Orders typically take 2-3 business days to process and in-stock items will usually be delivered 3-5 days from the date that they ship (depending on origin and destination). If there is a delay, you will be notified by email. No signature is required for standard ground shipping, so you may want to make arrangements to have packages brought inside soon after delivery, if you are unable to receive it in person.
Storage & Handling
Follow the storage instructions on your product label and the information supplied with your batch. Storage and handling requirements vary by product and presentation.
Tesamorelin has been developed and studied for a specific condition involving excess visceral abdominal fat. That is different from offering it as a general weight management product.
Specialist medical information about its defined indication and formulation.
The PHI Perspective
Clinical evidence is strongest when the patient group and product match. We keep that distinction visible.
For clinician-directed use only where permitted.
How It Works
It prompts growth hormone release through a natural signalling pathway. Its medical evidence concerns defined patients and treatment conditions.
What the Research SuggestsThe strongest clinical evidence concerns a defined medical indication involving HIV associated lipodystrophy. It does not establish general weight loss benefits or make every supplied preparation equivalent.
Evidence level: Human trials and a defined medical indication for licensed tesamorelin. Not an approval of this PHI vial.
Storage & Handling
Store lyophilised vial at 2-8 C, protected from light.
Active compound: Tesamorelin (trans-3-hexenoyl-GHRH 1-44 analogue)
Mechanism of ActionBinds the GHRH receptor on anterior pituitary somatotrophs, stimulating pulsatile endogenous growth hormone release and consequent hepatic IGF-1 production. Growth hormone promotes lipolysis in visceral adipose tissue preferentially over subcutaneous depots, which accounts for the specificity of the observed effect.
Clinical Evidence BaseTwo Phase III randomised placebo-controlled trials in HIV-associated lipodystrophy demonstrated significant reduction in visceral adipose tissue, supporting FDA approval. Subsequent randomised trials reported reduction in hepatic fat and slowed fibrosis progression in NAFLD. Evidence in the general population without lipodystrophy is limited.
Safety & PrecautionsAdverse effects reflect growth hormone elevation: arthralgia, peripheral oedema, myalgia, paraesthesia and injection-site reactions. Impaired glucose tolerance and increased blood glucose occur and require monitoring, particularly in patients with diabetes or pre-diabetes. Contraindicated in active malignancy given IGF-1 elevation, in pituitary disease and in pregnancy. Baseline and periodic IGF-1 and glucose monitoring should be standard. Benefit is not maintained after discontinuation.
ContraindicationsActive malignancy; disruption of the hypothalamic-pituitary axis or pituitary tumour; pregnancy; known hypersensitivity to tesamorelin or mannitol.
Literature & ReferencesFalutz J et al. N Engl J Med, 2007 - tesamorelin and visceral adipose tissue in HIV-associated lipodystrophy. | Falutz J et al. J Acquir Immune Defic Syndr, 2010 - Phase III long-term efficacy and safety. | Stanley TL et al. Lancet HIV, 2019 - tesamorelin for hepatic fat in HIV-associated NAFLD. | US FDA prescribing information, Egrifta (tesamorelin for injection).
Related Products
Ipamorelin Vial
Available in multiple doses
MOTS-c Vial
Available in multiple doses
CJC-1295 DAC Vial
Available in multiple doses
